Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin
about
Focus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infectionsCurrent concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococciStructural features and kinetic characterization of alanine racemase fromStaphylococcus aureus(Mu50)Endophytic fungi: a reservoir of antibacterialsGlucose Augments Killing Efficiency of Daptomycin Challenged Staphylococcus aureus PersistersWhole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureusA mutation in the PP2C phosphatase gene in a Staphylococcus aureus USA300 clinical isolate with reduced susceptibility to vancomycin and daptomycin.In vitro and in vivo activities of antibiotic PM181104.Synergism between a novel chimeric lysin and oxacillin protects against infection by methicillin-resistant Staphylococcus aureus.Development of improved inhibitors of wall teichoic acid biosynthesis with potent activity against Staphylococcus aureus.The potential economic value of a Staphylococcus aureus vaccine for neonatesDaptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect")Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanismsClinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.Staphylococcus aureus in continuous culture: a tool for the rational design of antibiotic treatment protocolsNadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771.Heterogeneity of mprF sequences in methicillin-resistant Staphylococcus aureus clinical isolates: role in cross-resistance between daptomycin and host defense antimicrobial peptides.Increased cell wall teichoic acid production and D-alanylation are common phenotypes among daptomycin-resistant methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates.Comparative genome sequencing of an isogenic pair of USA800 clinical methicillin-resistant Staphylococcus aureus isolates obtained before and after daptomycin treatment failure.Correlation of daptomycin resistance in a clinical Staphylococcus aureus strain with increased cell wall teichoic acid production and D-alanylation.Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant Staphylococcus aureus infections.In vitro cross-resistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus isolates.Phenotypic and genotypic characterization of daptomycin-resistant methicillin-resistant Staphylococcus aureus strains: relative roles of mprF and dlt operons[Resistance to "last resort" antibiotics in Gram-positive cocci: The post-vancomycin era].Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium.Staphylococcus aureus metabolic adaptations during the transition from a daptomycin susceptibility phenotype to a daptomycin nonsusceptibility phenotype.In Vivo Pharmacodynamic Evaluation of an FtsZ Inhibitor, TXA-709, and Its Active Metabolite, TXA-707, in a Murine Neutropenic Thigh Infection Model.Telavancin in therapy of experimental aortic valve endocarditis in rabbits due to daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus.Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in TaiwanBiochemical characterization of cardiolipin synthase mutations associated with daptomycin resistance in enterococci.Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections.Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections.An antibacterial from Hypericum acmosepalum inhibits ATP-dependent MurE ligase from Mycobacterium tuberculosis.Burden of methicillin-resistant Staphylococcus aureus: focus on clinical and economic outcomes.Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus.Daptomycin and tigecycline: a review of clinical efficacy in the antimicrobial era.The evaluation and treatment of complicated skin and skin structure infections.Prescribing trends with daptomycin (cubicin) for the treatment of gram-positive infectionsRegulation of mprF in daptomycin-nonsusceptible Staphylococcus aureus strains
P2860
Q26746197-21040B5E-76BF-4053-8F4D-8B4029A18A40Q26853465-B6B4E2CF-C24D-493C-95F5-D5EE865A5769Q27676379-94B721EA-EE17-46B9-A7A9-5E79DF7F3E8CQ28083549-FD67B270-5A55-44E6-8E66-4E626B21E37DQ28550612-62026DB1-7419-465F-A38B-CA8531F3EC53Q28740293-6E598D10-F01D-4B75-BEB4-4253B805A014Q30455758-81C42FEA-B683-4D35-8126-9E790A70957BQ31126282-6DB5783F-9865-4D1A-9215-30AE237CE075Q33525230-FD68592A-CFD0-4481-B716-A8BDA110546FQ33529977-56C18417-787A-4215-9CFD-542AC32E6884Q33958347-F475A780-83AD-48B8-A3A7-93B2E3CE2920Q34045273-BA590008-85B2-4EDB-B2E6-8FBDE75FEE17Q34045376-EEB630BD-0877-4CBB-A3B0-A6E9D5C7ACC8Q34157657-F24D1DB3-10F4-4AB3-AFC3-111B429E7ECAQ34387384-5EEA370A-5456-4141-8085-911369ACCD4BQ34571545-54EB72E0-A2FD-4358-8BFF-E2C674E00EB0Q34597770-AE3A4AFB-4B4D-48C7-8960-7F43F7304441Q34779009-81BE3C77-B9BD-4B7F-8EDD-3FA5E73A3494Q34932588-BB44FF35-D40C-454D-8156-BA05484CC963Q35139449-DC7B3130-D1E2-496C-91AE-E08AFAE6DC21Q35169018-0F3F6C6F-F994-4A83-AE8B-492059C1A560Q35191555-30F79175-742B-44C6-B2D8-928BB9EC19D7Q35256159-2BCC856F-CB5F-4DCF-8537-E41EB21638E4Q35619094-28760C7B-EA5A-4CF4-AE30-111DFB60D0A0Q35689222-788E4196-8824-44DB-A129-AEEAC277A5DEQ35746096-7A35FA92-46BF-4DE1-A0E7-65D866EA1AF9Q36076047-02E6BA4E-CD16-4A23-B5FD-ABD7877199D1Q36364106-59F7592E-B2CA-44E7-97AA-B523772C3AA1Q36422686-736CA747-40D7-4326-91B4-E20EB31CBD34Q36497876-F0FF8078-B096-4DAD-AD0D-8154205295ABQ36505466-71BC1681-F8FC-46D1-BE8A-00D6A3F433E0Q36718474-A5161B6F-4754-433E-B128-06BF5002AD92Q36777821-ADA28434-B8D0-43D3-A7D7-296BB3B5ABB8Q36852681-5D895308-1443-4499-BF8A-43DCB18D058AQ36861645-C6F9FC8F-7935-48A2-BE6F-B51B34C75DA3Q36903680-CBAA67B9-1789-4161-A84B-7F933057C111Q36967265-8F4E7392-EE5A-4805-BF21-87DF37114E49Q37111836-68773322-6EB2-4AD1-AAA6-46D93FBB0CE8Q37195896-42ABA0C4-55B8-4F5E-91C0-1162D6606E17Q37204125-3BBDCC65-68C4-4C59-94E4-0CFF30CDED23
P2860
Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin
@ast
Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin
@en
type
label
Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin
@ast
Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin
@en
prefLabel
Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin
@ast
Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin
@en
P2860
P1476
Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin
@en
P2093
Daniel J Skiest
P2860
P304
P356
10.1128/JCM.44.2.655-656.2006
P407
P577
2006-02-01T00:00:00Z